GPRASP1保护内皮天冬氨酸代谢预防HFpEF相关肺动脉高压
本研究探讨GPRASP1在射血分数保留心力衰竭相关肺动脉高压(PH-HFpEF)内皮功能障碍中的作用。通过内皮特异性Gprasp1敲除小鼠及多组学分析发现,GPRASP1缺失导致天冬氨酸代谢偏向天冬酰胺合成,引发线粒体能量障碍和一氧化氮缺乏。恢复GPRASP1表达或奥洛他定抑制ASNS可改善心肺病理。
要点
- GPRASP1缺失损害三羧酸循环,导致一氧化氮缺乏和内皮功能障碍。
- GPRASP1通过PRKN依赖的泛素化降解ASNS,维持天冬氨酸代谢平衡。
- 奥洛他定抑制ASNS活性可改善PH-HFpEF模型心肺病理。
核心结论
- GPRASP1通过非经典途径维持肺内皮稳态,GPRASP1-PRKN-ASNS轴连接蛋白质稳态与内皮代谢完整性。
- 天冬氨酸代谢是PH-HFpEF中可靶向的代谢脆弱点。
研究设计与样本
- 采用PH-HFpEF小鼠模型进行转录组谱分析,并构建内皮特异性GPRASP1敲除小鼠。
- 运用多模态代谢组学、同位素示踪、蛋白质组学和机制生化实验描绘下游通路。
主要发现
- PH-HFpEF模型肺内皮细胞中GPRASP1显著降低。
- 内皮Gprasp1敲除小鼠表现肺血管重构、肺动脉压升高、舒张功能障碍及糖脂代谢异常。
- GPRASP1缺失通过稳定ASNS使天冬氨酸偏向天冬酰胺合成而非草酰乙酸生成,损害三羧酸循环活性。
- 代谢重编程导致三磷酸腺苷耗竭、活性氧蓄积、内皮型一氧化氮合酶解偶联及一氧化氮缺乏。
- GPRASP1作为非经典衔接蛋白支架E3泛素连接酶PRKN与ASNS,促进PRKN依赖的K48连接泛素化和ASNS蛋白酶体降解。
临床怎么用
- 奥洛他定作为ASNS活性抑制剂可能是PH-HFpEF的潜在治疗药物。
- 评估肺内皮GPRASP1水平或可辅助识别PH-HFpEF高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary hypertension (PH) is a serious complication of heart failure with preserved ejection fraction (HFpEF), for which no targeted therapies are currently available. Endothelial dysfunction plays a crucial role in PH associated with HFpEF (PH-HFpEF), yet its molecular drivers remain poorly defined. METHODS: Transcriptome profiling uncovered endothelial characteristics of PH-HFpEF. Endothelial-specific GPRASP1 (GPCR [G protein-coupled receptor]-associated sorting protein 1 deletion in mice was conducted to investigate its participation in PH-HFpEF pathology. Multimodal metabolomics, isotope tracing, proteomics, and mechanistic biochemical assays were used to map downstream pathways and identify druggable mediators. RESULTS: GPRASP1 was significantly lowered in pulmonary endothelial cells of PH-HFpEF models. Endothelial Gprasp1 knockout mice exhibited major PH-HFpEF features, including pulmonary vascular remodeling, elevated pulmonary pressure, diastolic dysfunction, and abnormal glucose/lipid metabolism. GPRASP1 loss impaired tricarboxylic acid cycle activity by stabilizing ASNS (asparagine synthetase), preferentially shifting aspartate toward asparagine synthesis over oxaloacetate production. This metabolic reprogramming led to adenosine triphosphate depletion, reactive oxygen species accumulation, endothelial nitric oxide synthase uncoupling, and nitric oxide deficiency. We discovered that, beyond its classic role in GPCR sorting, GPRASP1 functioned as a noncanonical adaptor protein that scaffolded the E3 ubiquitin ligase PRKN (Parkin) and ASNS, promoting PRKN-dependent K48-linked ubiquitination and proteasomal degradation of ASNS via its C-terminal domain. In parallel, under mitochondrial stress, GPRASP1 strengthened PRKN interactions with MFN1/2, enhanced their K63-linked ubiquitination, and facilitated PRKN-mediated mitophagy. Restoration of GPRASP1 expression or pharmacological inhibition of ASNS activity with olopatadine normalized aspartate utilization, improved mitochondrial bioenergetics, rescued endothelial function, and attenuated cardiopulmonary pathology in PH-HFpEF models. CONCLUSIONS: Our findings unlocked a noncanonical role of GPRASP1 in preserving pulmonary endothelial homeostasis and delineated a novel GPRASP1-PRKN-ASNS axis that connected proteostasis with endothelial metabolic integrity, highlighting aspartate metabolism as a targetable vulnerability in cardiopulmonary disease.
引用
- Li, Tang, Ding, et al. GPRASP1 Safeguards Endothelial Aspartate Metabolism to Prevent Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. Circulation. 2026. PMID: 42093650. doi:10.1161/CIRCULATIONAHA.126.079030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。